Crenza Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 50.00 K
as on 16-11-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.20 Cr
as on 16-11-2024
- Revenue 492.29%
(FY 2023)
- Profit 328.84%
(FY 2023)
- Ebitda 112.69%
(FY 2023)
- Net Worth 134.65%
(FY 2023)
- Total Assets 20.00%
(FY 2023)
About Crenza Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 50.00 K .
The company currently has active open charges totaling ₹1.20 Cr.
Sandhya Pittala and Satyanarayana Pittala serve as directors at the Company.
- CIN/LLPIN
U24304TG2017PTC117228
- Company No.
117228
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2017
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Crenza Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandhya Pittala  | Whole-Time Director | 22-May-2017 | Current |
| Satyanarayana Pittala | Director | 30-May-2019 | Current |
Financial Performance of Crenza Pharmaceuticals.
Crenza Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 492.29% increase. The company also saw a substantial improvement in profitability, with a 328.84% increase in profit. The company's net worth Soared by an impressive increase of 134.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Crenza Pharmaceuticals?
In 2023, Crenza Pharmaceuticals had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 May 2023 | ₹1.20 Cr | Open |
How Many Employees Work at Crenza Pharmaceuticals?
Crenza Pharmaceuticals has a workforce of 31 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crenza Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crenza Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
